MBBS OSCE · General Surgery / Gastroenterology

OSCE — suspected gastric cancer with Virchow node

OSCE station on advanced gastric cancer presentation, metastatic eponyms, staging pathway including laparoscopy, and resectable vs palliative pathways with FLOT and D2 principles.

On this page
Study tools

Exam tags

NEET-PGINICETUSMLEPLAB

Brief (to candidate)

A 58-year-old man with early satiety, epigastric pain, and weight loss has a hard epigastric mass and a left supraclavicular node. Hb 8.8 g/dL. Assess and plan management in 8 minutes.

Candidate instructions

  1. Focused history (dyspepsia alarms, H. pylori, smoking, family/CDH1 clues).
  2. Examine for Virchow, SMJ nodule, ascites, DRE/Blumer if relevant.
  3. State stage implication of Virchow node.
  4. Outline investigation ladder including staging laparoscopy for potentially resectable cases.
  5. Contrast palliative systemic pathway vs D2 gastrectomy + perioperative FLOT for localised disease.

Examiner checklist

DomainExpected
Exam eponymsVirchow/Troisier = stage IV; SMJ, Krukenberg, Blumer
PathogenesisCorrea cascade; H. pylori Class I; Lauren types
StagingOGD multi-biopsy; CT CAP; staging laparoscopy; HER2
Curative pathSubtotal/total + D2; perioperative FLOT (not FOLFIRINOX)
SupportiveNutrition; B12 lifelong after total gastrectomy
CommunicationHonest prognosis; MDT; palliative care if metastatic

Common errors

  • Offering curative gastrectomy without staging out peritoneal disease.
  • Naming mFOLFIRINOX as gastric adjuvant.
  • Missing H. pylori eradication opportunity in earlier disease.

Model key actions

  • Virchow node = stage IV until full staging; do not offer futile radical surgery without excluding peritoneal disease.
  • OGD with multiple biopsies; CT CAP; staging laparoscopy for cT2+/equivocal M0.
  • Resectable: perioperative FLOT + gastrectomy with spleen-preserving D2.
  • Metastatic HER2+ may receive trastuzumab-containing systemic therapy; early nutrition and palliative care.

Communication points

  • Explain need for endoscopy and staging before any operation.
  • Discuss H. pylori as Class I carcinogen and eradication when residual stomach remains.
  • Lifelong B12 after total gastrectomy; dumping diet education.
References3Show
  1. [1]Sundar R, Nakayama I, Markar SR, et al. Gastric cancer. Lancet, 2025.PMID 40319897
  2. [3]Songun I, Putter H, Kranenbarg EM, et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol, 2010.PMID 20409751
  3. [2]Duan Y, Xu Y, Dou Y, et al. Helicobacter pylori and gastric cancer: mechanisms and new perspectives. Review, 2025.PMID 39849657
OSCE — suspected gastric cancer with Virchow node · MBBS OSCE · NeetVellum